UAE tremfya market report size, share, growth drivers, trends, opportunities & forecast 2025–2030

UAE Tremfya Market Overview

• The UAE Tremfya Market is valued at USD 20 million, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of chronic inflammatory diseases such as psoriasis and psoriatic arthritis, rising healthcare expenditure, advancements in biologic therapies, and the expanding adoption of IL-23 inhibitors. The market is further supported by enhanced disease awareness, government-backed healthcare modernization, and improved access to biologics through both public and private insurance coverage.
• Dubai and Abu Dhabi are the dominant cities in the UAE Tremfya Market due to their advanced healthcare infrastructure, high population density, and a significant number of healthcare facilities. These cities attract a large number of patients seeking specialized treatments, which further drives the demand for Tremfya and similar biologic therapies. The presence of major tertiary care hospitals and international clinics in these emirates also promotes early diagnosis and prescription of advanced biologics.
• In 2023, the UAE Ministry of Health and Prevention issued the "Guideline for Pharmacovigilance of Biologic Medicines, 2023," mandating that all biologic therapies, including Tremfya, must undergo a comprehensive pharmacovigilance program. This regulation requires marketing authorization holders to establish robust systems for adverse event reporting, periodic safety updates, and risk management plans, thereby enhancing patient safety and ensuring continuous monitoring of drug efficacy and adverse effects.

UAE Tremfya Market Segmentation

By Indication:The Tremfya market is segmented by indication into three subsegments: Plaque Psoriasis, Psoriatic Arthritis, and Other Chronic Inflammatory Diseases. Among these, Plaque Psoriasis is the leading subsegment, driven by its high prevalence and the increasing number of patients seeking effective treatment options. The growing awareness of the disease, early diagnosis initiatives, and the availability of advanced biologic therapies contribute to its dominance.

By Distribution Channel:The market is also segmented by distribution channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies dominate this segment due to their direct access to patients requiring immediate treatment and the availability of specialized healthcare professionals who can provide guidance on biologic therapies. The increasing role of hospital-based specialty clinics and structured procurement channels further strengthens this dominance.

UAE Tremfya Market Competitive Landscape

The UAE Tremfya Market is characterized by a dynamic mix of regional and international players. Leading participants such as Janssen Pharmaceuticals (Johnson & Johnson Middle East FZ-LLC), AbbVie Biopharmaceuticals GmbH (UAE), Amgen Middle East FZ-LLC, Novartis Middle East FZE, Sanofi Gulf FZ-LLC, Merck Sharp & Dohme (MSD) Gulf, GlaxoSmithKline (GSK Gulf FZ-LLC), Eli Lilly and Company (Lilly Middle East), Pfizer Gulf FZ-LLC, Roche Middle East FZ-LLC, Biogen International GmbH (Dubai), Regeneron Pharmaceuticals (Regional Office), Sandoz Middle East, Teva Pharmaceutical Industries Ltd. (Dubai), and Astellas Pharma Middle East FZE contribute to innovation, geographic expansion, and service delivery in this space.

UAE Tremfya Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Psoriasis:The UAE has witnessed a significant rise in psoriasis cases, with approximately 2.5% of the population affected, translating to around 250,000 individuals. This increase is attributed to lifestyle changes and environmental factors. The growing patient base is driving demand for effective treatments like Tremfya, which is known for its efficacy in managing moderate to severe psoriasis. As awareness of the condition rises, more patients are seeking treatment, further propelling market growth.
• Rising Healthcare Expenditure:The UAE's healthcare expenditure is projected to reach AED 88 billion (approximately USD 21 billion) in future, reflecting a 5% annual increase. This rise is driven by government initiatives to enhance healthcare infrastructure and services. Increased funding allows for better access to advanced treatments, including Tremfya, which is crucial for managing chronic conditions like psoriasis. Enhanced healthcare spending is expected to facilitate the adoption of innovative therapies, thereby boosting market growth.
• Advancements in Biotechnology:The UAE is investing heavily in biotechnology, with the sector expected to grow to AED 10 billion (approximately USD 2.7 billion) in future. This investment fosters innovation in drug development, particularly for biologics like Tremfya. The emergence of new biopharmaceuticals enhances treatment options for psoriasis, attracting more patients. As biotechnology continues to evolve, it will likely lead to more effective therapies, further stimulating market demand and improving patient outcomes.

Market Challenges

• High Cost of Treatment:The cost of Tremfya can exceed AED 30,000 (approximately USD 8,200) annually per patient, posing a significant barrier to access for many individuals. This high price point limits treatment uptake, particularly among lower-income patients. The financial burden associated with biologic therapies can deter patients from seeking necessary care, thereby hindering market growth. Addressing affordability is crucial for expanding access to effective psoriasis treatments in the UAE.
• Limited Access to Healthcare Facilities:Despite advancements, many regions in the UAE still face challenges in healthcare access, particularly in rural areas. Approximately 20% of the population lives in remote locations with limited healthcare infrastructure. This disparity restricts patients' ability to receive timely diagnoses and treatments for psoriasis. The lack of specialized dermatology services in these areas can impede the overall market growth for Tremfya and similar therapies, necessitating targeted interventions.

UAE Tremfya Market Future Outlook

The UAE Tremfya market is poised for significant growth, driven by increasing awareness of psoriasis and the benefits of biologic therapies. As healthcare expenditure rises, more patients will gain access to advanced treatments. Additionally, the integration of digital health solutions will enhance patient engagement and adherence to treatment regimens. The focus on personalized medicine will further tailor therapies to individual patient needs, improving outcomes and satisfaction in the long term.

Market Opportunities

• Expansion of Telemedicine Services:The UAE's telemedicine market is expected to grow to AED 1.5 billion (approximately USD 408 million) in future. This growth presents an opportunity for Tremfya to reach patients in remote areas, improving access to care. Telemedicine can facilitate consultations and follow-ups, ensuring patients receive timely treatment and support, thereby enhancing overall market penetration.
• Collaborations with Local Healthcare Providers:Strategic partnerships with local healthcare providers can enhance Tremfya's market presence. Collaborations can lead to improved distribution channels and better patient education initiatives. By working closely with healthcare professionals, manufacturers can ensure that patients are informed about treatment options, increasing the likelihood of adoption and adherence to therapy, ultimately driving market growth.